NASDAQ:OLMA

Olema Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy OLMA

*Your capital is at risk

$10.51

-0.180 (-1.68%)

At Close: Jun 03, 2026

Olema Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -50.62. In total, the insiders bought 3.91M and sold 1.26M OLMA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-50.62
● Buy	3.91M shares
● Sell	1.26M shares
64% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Feb 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -50.62. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 19, 2025 Buy	Common Stock M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	40 000 Value: $610.0K
Dec 19, 2025 Sell	Common Stock G-Gift	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	9 000 Value: $0
Dec 19, 2025 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	6 046 Value: $189.8K
Dec 19, 2025 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	1 225 Value: $34.4K
Dec 19, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Clark Ian T Director	Director	21 520 Value: $77.7K
Dec 19, 2025 Sell	Common Stock S-Sale	Clark Ian T Director	Director	41 840 Value: $1.28M
Dec 19, 2025 Sell	Common Stock S-Sale	Clark Ian T Director	Director	193 056 Value: $5.74M
Dec 19, 2025 Buy	Common Stock M-Exempt	Clark Ian T Director	Director	21 520 Value: $77.7K
Dec 19, 2025 Buy	Common Stock M-Exempt	Clark Ian T Director	Director	21 520 Value: $168.7K
Dec 19, 2025 Buy	Common Stock M-Exempt	Clark Ian T Director	Director	12 070 Value: $49.2K
Dec 19, 2025 Sell	Common Stock S-Sale	Clark Ian T Director	Director	29 904 Value: $862.1K
Dec 19, 2025 Sell	Common Stock S-Sale	Zojwalla Naseem Chief Medical Officer	Officer	57 079 Value: $1.60M
Dec 19, 2025 Buy	Common Stock M-Exempt	Clark Ian T Director	Director	209 690 Value: $923.9K
Dec 19, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Clark Ian T Director	Director	12 070 Value: $49.2K
Dec 19, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Clark Ian T Director	Director	209 690 Value: $923.9K
Dec 19, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Clark Ian T Director	Director	21 520 Value: $168.7K
Dec 19, 2025 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	43 729 Value: $1.33M
Dec 08, 2025 Sell	Common Stock G-Gift	Kovacs Shane William Charles Ch. Operating & Financial Off.	Officer	75 000 Value: $0
Nov 26, 2025 Sell	Common Stock G-Gift	Kovacs Shane William Charles Ch. Operating & Financial Off.	Officer	225 000 Value: $0
Nov 25, 2025 Sell	Common Stock G-Gift	Rappaport Andrew Director	Director	35 868 Value: $0
Nov 21, 2025 Buy	Common Stock M-Exempt	Rappaport Andrew Director	Director	35 868 Value: $14.0K
Nov 21, 2025 Buy	Stock Option (right to buy) M-Exempt	Rappaport Andrew Director	Director	35 868 Value: $14.0K
Sep 18, 2025 Sell	Common Stock S-Sale	Harmon Cyrus Director	Director	10 000 Value: $83.3K
Sep 18, 2025 Sell	Common Stock S-Sale	Harmon Cyrus Director	Director	3 086 Value: $25.7K
Sep 18, 2025 Sell	Common Stock S-Sale	Harmon Cyrus Director	Director	3 086 Value: $25.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negativ...

Read Full Profile Here